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AbstrAct
Objectives The cluster randomised trial of the Data-
driven Quality Improvement in Primary Care (DQIP) 
intervention showed that education, informatics and 
financial incentives for general medical practices to 
review patients with ongoing high-risk prescribing of 
non-steroidal  
anti-inflammatory drugs and antiplatelets reduced the 
primary end point of high-risk prescribing by 37%, 
where both ongoing and new high-risk prescribing 
were significantly reduced. This quantitative process 
evaluation examined practice factors associated with (1) 
participation in the DQIP trial, (2) review activity (extent 
and nature of documented reviews) and (3) practice 
level effectiveness (relative reductions in the primary 
end point).
setting/participants Invited practices recruited  
(n=33) and not recruited (n=32) to the DQIP trial in  
Scotland, UK.
Outcome measures (1) Characteristics of recruited 
versus non-recruited practices. Associations of 
(2) practice characteristics and ‘adoption’ (self-
reported implementation work done by practices) 
with documented review activity and (3) of practice 
characteristics, DQIP adoption and review activity with 
effectiveness.
results (1) Recruited practices had lower performance 
in the quality and outcomes framework than those 
declining participation. (2) Not being an approved 
general practitioner training practice and higher self-
reported adoption were significantly associated with 
higher review activity. (3) Effectiveness ranged from a 
relative increase in high-risk prescribing of 24.1% to a 
relative reduction of 77.2%. High-risk prescribing and 
DQIP adoption (but not documented review activity) were 
significantly associated with greater effectiveness in the 
final multivariate model, explaining 64.0% of variation in 
effectiveness.
conclusions Intervention implementation and 
effectiveness of the DQIP intervention varied 
substantially between practices. Although the DQIP 
intervention primarily targeted review of ongoing high-
risk prescribing, the finding that self-reported DQIP 
adoption was a stronger predictor of effectiveness than 
documented review activity supports that reducing 
initiation and/or re-initiation of high-risk prescribing is 
key to its effectiveness.
trial registration number NCT01425502; Post-results.
IntrOductIOn
High-risk prescribing in primary care
High-risk prescribing in primary care is a 
major concern for healthcare systems inter-
nationally. Between 2% and 4% of emergency 
hospital admissions are caused by preventable 
adverse drug events.1 2 The National Insti-
tute of Clinical Excellence (NICE) estimated 
in 2015 that avoidable drug-related admis-
sions in England cost £530 million per year3 
and in the USA the combined cost of drug- 
related hospital admissions, emergency 
department and outpatient visits was esti-
mated at $19.6 billion in 2013.4 A large 
proportion of these admissions are caused by 
high-risk prescribing of commonly prescribed 
Process evaluation of the Data-driven 
Quality Improvement in Primary Care 
(DQIP) trial: quantitative examination of 
variation between practices in recruitment, 
implementation and effectiveness
Tobias Dreischulte,1,2 Aileen Grant,3 Adrian Hapca,2 Bruce Guthrie2
To cite: Dreischulte T, Grant A, 
Hapca A, et al.  Process 
evaluation of the Data-
driven Quality Improvement 
in Primary Care (DQIP) trial: 
quantitative examination of 
variation between practices in 
recruitment, implementation 
and effectiveness. BMJ Open 
2018;8:e017133. doi:10.1136/
bmjopen-2017-017133
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2017- 
017133).
Received 9 August 2017
Revised 3 October 2017
Accepted 1 November 2017
1Prescribing Support Unit, NHS 
Tayside, Dundee, UK
2Population Health Sciences 
Division, Medical Research 
Institute, University of Dundee, 
Dundee, UK
3School of Nursing and 
Midwifery, Robert Gordon 
University, Aberdeen, UK, 
Scotland
correspondence to
Dr Tobias Dreischulte;  
 t. dreischulte@ dundee. ac. uk
Research
strengths and limitations of this study
 ► A major strength of this study is the collection of 
detailed quantitative data on individual practices’ 
responses to the Data-driven Quality Improvement 
in Primary Care intervention, which enabled 
examination of substantial heterogeneity in both 
the implementation of intervention processes and 
effectiveness, thereby complementing qualitative 
case studies examining practitioners’ perceptions of 
practices’ responses.
 ► A limitation of the study is that the sample size was 
small (33 practices) implying relatively limited power 
for identifying practice characteristics significantly 
associated with trial participation, and for examining 
variation in intervention implementation and 
outcomes. 
 ► A further limitation of the study is the use of a 
questionnaire (to measure the adoption of the 
intervention by general practices), which has not 
undergone formal psychometric testing.
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Figure 1 Framework model for designing process evaluations of cluster-randomised controlled trials applied to the  
Data-driven Quality Improvement in Primary Care (DQIP) trial.
drugs, with non-steroidal anti-inflammatory drugs 
(NSAIDs) and antiplatelets being the main or among the 
main drugs implicated, causing gastrointestinal, cardio-
vascular and renal adverse events.5–7 
data-driven Quality Improvement in Primary care intervention 
and trial
In the UK, virtually all primary care prescribing is done 
by general practitioners (GP). The Data-driven Quality 
Improvement in Primary Care (DQIP) intervention was 
systematically developed and optimised8–10 and comprised 
three intervention components: (1) professional educa-
tion about the risks of NSAIDs and antiplatelets via an 
outreach visit by a pharmacist; (2) financial incentives 
to review patients at the highest risk of NSAID and anti-
platelet adverse drug events, split into a participation fee 
of £350 and £15 per patient reviewed and (3) access to a 
web-based IT tool to identify such patients and support 
structured review. The DQIP intervention was evaluated 
in a pragmatic cluster randomised controlled stepped 
wedge trial in 33 practices from one Scottish health 
board, where all participating practices received the 
intervention but were randomised to one of 10 different 
start dates.11 Across all practices, targeted high-risk 
prescribing fell from 3.7% immediately before to 2.2% 
at the end of the intervention period (adjusted OR 0.63 
(95% CI 0.57 to 0.68), P<0.0001). The intervention only 
incentivised review of ongoing high-risk prescribing, but 
led to reductions in both ongoing (1.5% at end vs 2.6% 
preintervention, adjusted OR 0.60 (95% CI 0.53 to 0.67), 
P<0.001) and ‘new’ high-risk prescribing (0.7% vs 1.0%, 
adjusted OR 0.77 (0.68 to 0.87), P<0.001) and notably, 
reductions in high-risk prescribing were sustained in the 
year after financial incentives stopped. In addition, there 
were significant reductions in emergency hospital admis-
sions with gastrointestinal ulcer or bleeding (from 55.7 
to 37.0/10 000 person-years, relative risk (RR) 0.66 (95% 
CI 0.51 to 0.86), P=0.002), and heart failure (from 708 to 
513/10 000 person-years, RR 0.73 (95% CI 0.56 to 0.95), 
P=0.02).12
Process evaluation of the dQIP intervention
Descriptions of complex interventions in the research 
literature often lack details about the context in which 
interventions were delivered and about the processes of 
intervention delivery and implementation of individual 
intervention components.13–16 Such details are however 
important to decide whether and how an intervention 
can be implemented in routine care and to inform future 
research.14 15 We therefore carried out a comprehensive 
mixed-methods process evaluation alongside the main 
DQIP trial, based on a cluster-randomised trial process- 
evaluation framework17 which we developed drawing on 
the general literature on process evaluation, published 
process evaluations and the RE-AIM framework.18 Our 
framework17 emphasises the importance of considering 
two levels of intervention delivery and response that 
often characterise cluster-randomised trials of behaviour 
change interventions (although their relative importance 
will depend on intervention design). The first is the 
intervention that is delivered to clusters, which respond 
by adopting (or not) the intervention and integrating it 
with existing work. The second is the desired change in 
care which the cluster professionals deliver to individual 
patients. Figure 1 shows the application of the framework 
to the DQIP intervention. In DQIP, the delivery of the 
intervention to professionals was predefined, intended 
to be delivered with high fidelity across all practices and 
under the control of the research team, whereas the inter-
vention delivered to patients was largely at the discretion 
of practices, who decided whether and how they reviewed 
patients and whether to stop or otherwise proactively 
manage high-risk prescribing in those reviewed. This is 
similar to most health service interventions of this nature, 
where primary care organisations deliver an intervention 
to practices (eg, contractual changes, financial incentives, 
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education and so on), but have relatively little control 
over whether or how practices implement the intended 
care for patients. We used this framework to structure our 
parallel process evaluation, mapping data collection to a 
logic model of how the DQIP intervention was expected 
to work.17
Focus of this paper
Understanding cluster factors associated with participa-
tion, implementation and effectiveness is important to 
understand how generalisable the findings are and how 
the intervention achieves (or fails to achieve) intended 
outcomes. Nevertheless, published evaluations of 
complex interventions rarely compare trial and target 
populations and often only report overall intervention 
impact. Additionally, process evaluations often largely 
assess participants’ perceptions of how interventions 
were implemented using qualitative methods, although 
many processes can usefully be examined quantitatively, 
providing potentially complementary findings about 
implementation. In this paper, we report the findings of 
prespecified quantitative analyses to examine (1) whether 
and how practices recruited to the DQIP trial differed 
from non-recruited ones; (2) whether practice character-
istics and practice-level response to the intervention deliv-
ered to them by the research team (subsequently referred 
to as adoption) were associated with the way the practice 
implemented delivering the intended change in care 
to patients (subsequently referred to as review activity); 
(3) whether practice characteristics, adoption and review 
activity were associated with intervention effectiveness at 
practice level.17
MetHOds
The design and methods of the overall process evalu-
ation have been described previously in the published 
protocol.17 In brief, the design was a mixed methods 
parallel process evaluation which examined a set of 
predefined processes and their associations with change 
in high-risk prescribing at practice level. The qualitative 
element consisted of comparative case studies in 10 of the 
33 participating practices, purposively sampled to include 
a mix of those initially responding and not responding 
to the intervention by rapidly reducing their high-risk 
prescribing, as judged by visual inspection of run charts 
approximately 4 months after practices started the inter-
vention. The case-study analysis of how practices adopted, 
implemented and maintained the intervention,19 and a 
detailed description of the intervention (including exam-
ples of materials used) with analysis of which interven-
tion components were more or less active and when this 
occurred are described separately.19 20 This paper reports 
the quantitative element of the process evaluation, which 
examined associations between practice characteristics, 
key intervention implementation processes and change 
in the high-risk NSAID and antiplatelet prescribing at 
practice level. The study was reviewed by the Fife and 
Forth Valley Research Ethics Committee (11/AL/0251).
dQIP trial study population
The study population comprised all NHS Tayside practices 
which participated in the DQIP trial. At practice level, the 
intervention period lasted 48 weeks from each practice’s 
randomised start date. At patient level, all patients regis-
tered with participating practices were included if they 
had at least one gastrointestinal, heart failure or renal 
risk factor that made them particularly vulnerable to the 
adverse effects of NSAIDs or antiplatelets (as defined by 
primary and secondary prescribing outcome measures).12 
Patients’ membership in the study cohort was dynamic 
because the presence of risk factors in individuals varies 
over time due to changing age, morbidity and copre-
scribing, and ended with the end of the 48-week DQIP 
intervention period in each practice, deregistration 
with a practice participating in DQIP, or death (which-
ever occurred first). Moving of patients between prac-
tices participating in the DQIP trial was accounted for 
by patients exiting and entering the respective practices’ 
cohorts at the point of registration with a new practice, 
although this was rare (<0.5% of patients).
data collection and variable definition
The characteristics of participating and non-participating 
practices (list size, rurality, socioeconomic deprivation, 
proportion of older people, postgraduate training status, 
overall quality and outcomes framework (QOF) clinical 
performance) were measured using publicly available 
data.21
Adoption. We conceptualised adoption as the work 
done by practices to prepare for and begin to deliver 
reviews to patients, and to ensure effective and sustained 
review. In order to further elicit whether and how prac-
tices responded to the intervention delivered to them by 
the research team in relation to adoption, the GP most 
involved in the DQIP work (nominated by the practice) 
completed two surveys, which were based on the four 
domains of Normalisation Process Theory,22 namely 
coherence (whether practices differentiate the inter-
vention from existing prescribing improvement work 
and understand and value intervention processes and 
aims), cognitive participation (whether practices engage 
with and plan to take collective action to implement 
the intervention), collective action (whether practices 
integrate the intervention into existing work and avoid 
disruptions to routine care) and reflexive monitoring 
(whether and how practices re-evaluate the intervention 
after attempting initial implementation and whether 
they modify practice processes if necessary). Given that 
there are no validated measures of these concepts, and 
constrained by the resources available, we pragmatically 
developed two instruments for use in an exploratory anal-
ysis (see online supplementary appendix 1 and 2).
In brief, a range of items were created with final item 
selection based on discussion with a panel of eight GPs 
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and/or normalisation process theory (NPT) experts 
to confirm content validity,23 and internal consistency 
was demonstrated for items targeting the same NPT 
constructs. The first survey was administered shortly 
after the educational outreach visit at the start of the 
intervention in each practice and asked respondents 
about their degree of agreement with statements 
relating to coherence (six items) and cognitive partici-
pation (five items). The second survey was administered 
6–9 months after practices started the intervention and 
asked respondents about their degree of agreement 
with statements on collective action (three items), and 
reflexive monitoring (four items) during intervention 
implementation. Agreement with the statements was 
measured on a 7-point Likert scale (1=strongly agree, 
4=neither agree nor disagree, 7=strongly disagree), 
with all statements being worded such that lower levels 
of agreement (higher numerical scores) indicated 
lower levels of coherence, cognitive participation, 
collective action and reflexive monitoring, respectively. 
Both surveys are provided in the appendix material. For 
each of the four NPT constructs, we transformed the 
agreement scale to an ‘achievement’ scale, so that the 
highest level of agreement with statements favouring 
each construct (agreement score=1) had the highest 
achievement score (achievement score=6), and the 
highest level of disagreement (agreement score=7) had 
the lowest achievement score (achievement score=0). 
Practices’ achievement was defined as the proportion of 
achieved over total maximum achievable scores across 
all questionnaire items that used these scales for each 
NPT construct.
Review activity was measured in terms of practice level 
reach, delivery to the patient and maintenance as spec-
ified in the published protocol17 (see figure 1). The 
DQIP IT tool provided data on reach (the proportion 
of patients flagged as needing a review over the 48-week 
intervention period, for whom the practice used the 
DQIP tool to record completion of a review), delivery 
to the patient (the proportion of eligible patients where 
there was an active change in treatment or proactive 
follow-up to determine appropriateness after initial 
records review) and maintenance (defined as reach in 
the final 24 weeks of the 48-week intervention period).
Effectiveness was measured using the trial primary 
outcome, which was a composite of nine individual high-
risk prescribing measures targeting high-risk NSAID and 
antiplatelet prescribing. In order to reduce chance effects 
(eg, in the context of measuring every 8 weeks, those 
arising from variable time intervals between prescriptions 
of a high-risk drug like NSAIDs and those relating to the 
small number of patients measured in some practices at 
single time-points), we defined effectiveness in each prac-
tice as the relative change in mean high-risk prescribing 
(measured using the trial primary outcome between 
the baseline 48 weeks before each practice started the 
intervention and the final 24 weeks of the intervention 
period).
statistical analysis
All analyses were conducted at cluster level. In order 
to inform judgements about generalisability (objective 
1), we compared recruited practices to those who were 
invited but declined participation. In order to examine 
variation between practices in the intended review activity 
(objective 2), we used univariate and multivariate linear 
regression to examine associations between practice char-
acteristics (list size, whether practices were accredited 
for postgraduate training, proportion of patients aged 
75 years or older, proportion of patients living in the most 
socioeconomically deprived areas and baseline high-risk 
prescribing) and the four measures of adoption (coher-
ence, cognitive participation, collective action, reflexive 
monitoring) with each of the three measures of review 
activity (reach, maintenance and delivery to the patient). 
In order to examine variation between practices in effec-
tiveness (objective 3), we used univariate and multivariate 
linear regression to study associations between practice 
characteristics, adoption and review activity with effective-
ness. Given our hypothesis that DQIP would drive review 
activity, which in turn would drive effectiveness, strong 
associations between adoption and review activity vari-
ables were expected. In order to explore such mediation 
effects, we therefore considered two multivariate models. 
The first only considered review activity variables and 
the second considered both adoption and review activity 
variables (in addition to practice characteristics). This 
allowed us to examine changes in the association between 
review activity and effectiveness after controlling for DQIP 
adoption. In all models, continuous explanatory variables 
were dichotomised as ‘high’ or ‘low’ using the median as 
a threshold. Multivariate modelling was conducted using 
stepwise elimination of variables that were not significant 
in each model at the P=0.10 level. Collinearity between 
variables was tested by examining the correlation coef-
ficients between each pair of explanatory variables and 
variance inflation factors (VIF). Where meaningful collin-
earity was identified between two explanatory variables, 
only the variable that yielded the better overall model fit 
was retained in the final model. To account for the small 
sample size, model fit was assessed using the adjusted 
R2.24 In sensitivity analyses, we repeated the above anal-
yses without dichotomising continuous variables.
results
comparison of recruited vs non-recruited practices
Among recruited practices the median (range) list size 
was 6167 (1367–11643), the median proportion of regis-
tered patients aged 75 years and older was 8.8% (5.9–
13.9), and the median proportion of patients living in the 
most deprived quintile of Scottish postcodes was 2.15% 
(0.00, 43.8). The median level of high-risk prescribing 
during the baseline period was 3.44% and varied more 
than sevenfold between practices (from 0.7% to 5.2%). 
Table 1 shows that participating practices had on average 
statistically significantly lower QOF performance than 
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Table 1 Characteristics of general practices recruited to the DQIP trial compared with eligible practices which declined to 
participate
Characteristic Recruited (n=34)*
Eligible but declined 
(n=32)† P value
Median (range) list size 6173 (1367 to 11803) 6551 (115 to 12 869) 0.348‡
Median (range) % aged ≥75 years 8.7 (5.7 to 14.1) 8.4 (0.0 to 18.1) 0.875‡
Median (range) % of registered patients resident in the 15% 
most deprived Scottish postcode areas
2.2 (0.0 to 43.8) 10.9 (0.0 to 61.8) 0.292‡
Median (range) % of registered patients resident in 
settlements of <3000 inhabitants
30.0 (5.8 to 64.1) 15.3 (4.8 to 41.1) 0.287‡
Contract type (nGMS vs other) 31 (91.2) 32 (100.0) 0.131§
Median (range) % of total QOF points achieved¶ 99.4 (83.5 to 100.0) 99.7 (94.5 to 100.0) 0.028*‡
GP postgraduate training accreditation 9 (26.5) 14 (43.8) 0.456§
*The total number of initially recruited practices. One practice dropped out before their allocated DQIP start date.
†Two additional practices which were involved in intervention optimisation and development were not eligible to be invited.
‡Mann-Whitney U test.
§χ2 test.
¶The QOF financially rewards primary care practices according to their performance on a range of clinical and organisational indicators, each 
of which is associated with a number of maximum achievable points, with each point corresponding to a defined payment. QOF scores range 
from 0 to 1000, with higher scores indicating better performance. The metric reported here represents the average proportion of maximum 
achievable points actually achieved by respective practices.
GP, general practitioner; nGMS, new general medical services contract; QOF, quality and outcomes framework.
practices who declined participation. Other differences 
were not statistically significant, although there were also 
reasonably substantial absolute differences in the propor-
tion of registered patients living in settlements of <3000 
inhabitants (30.0% in participating vs 15.3% in non-par-
ticipating), the proportion of registered patients living 
in the most deprived Scottish postcode areas (2.2% vs 
10.9%) and the proportion of practices accredited for GP 
training (26.5% vs 43.8%).
Variation in adoption, review activity and effectiveness
Adoption—response rates to questionnaires. All 33 practices 
in the trial completed the first adoption questionnaire 
(assessing coherence and cognitive participation before 
trial implementation) when they started the interven-
tion, and 29 practices (response rate 88%) completed 
the second questionnaire (assessing collective action and 
reflexive monitoring during initial implementation) 6–9 
months after they started the intervention. All items were 
completed in returned questionnaires.
Adoption—coherence and cognitive participation. At the 
start of the intervention in each practice, the median 
coherence and cognitive participation scores were 
77.8% (range 22.2–100.0) and 80.0% (range 26.7–100.0) 
reflecting that at the point of DQIP initiation, the 
majority of responding GPs indicated that they and their 
colleagues understood the work required (coherence 
questions A1.3 and A1.4), agreed that DQIP was worth-
while (coherence questions A1.5 and A1.6), expected 
that DQIP would lead to reductions in targeted high-
risk prescribing (cognitive participation question A1.7) 
and that all prescribers in the practice should and would 
get involved (cognitive participation question A1.8 
and A1.9). However, there were more mixed responses 
to questions about whether DQIP was different from 
existing NHS quality improvement work (coherence 
questions A1.1 and A1.2) (figure 2).
Adoption—collective action and reflexive monitoring. In 
comparison, at 6–9 months after the start of the interven-
tion in each practice, median levels of agreement with 
statements relating to collective action (66.7%, range 
11.1–100.0) and reflexive monitoring (66.7%, range 
16.7–100.0) during initial intervention implementation 
were somewhat lower. Less than half of practices (n=13) 
reported frequently using the DQIP IT tool to monitor 
progress in reducing high-risk prescribing (reflexive 
monitoring question A2.5), and less than a third (n=9) 
stated that DQIP had led to changes in practice processes, 
structures or systems beyond delivering the actual DQIP 
work (reflexive monitoring question A2.8). Nevertheless, 
over half of practices agreed that those involved in DQIP 
had the necessary skill set (collective action, question 
A2.1, 19 practices), that it was easy to integrate DQIP with 
existing work (collective action question A2.2, 19 prac-
tices) and that patients would respond well to medication 
changes (collective action question A2.3, 18 practices) 
(figure 2).
Review activity. The median proportion of patients with 
high-risk prescribing who had a review documented in 
the DQIP tool (reach) at any point during the DQIP 
intervention period was 78.8% (range 0.0%–100.0%), 
with a similar median reach of 75.0% (0%–100.0%) in 
the second half of the DQIP intervention period (main-
tenance). The median proportion of patients flagged 
as needing a review, who were judged to require proac-
tive follow-up at review (delivery to patient) was 39.7%, 
ranging from 0.0% to 83.3%.
group.bmj.com on January 9, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
6 Dreischulte T, et al. BMJ Open 2018;8:e017133. doi:10.1136/bmjopen-2017-017133
Open Access 
Figure 2 Findings from two adoption questionnaires completed by the general practitioner (GP) leading on Data-driven Quality 
Improvement in Primary Care (DQIP) in each practice.
Effectiveness. The median effectiveness was a relative 
reduction of 46.6%, ranging from a relative increase in 
high-risk prescribing of 24.1% to a relative reduction of 
77.2%.
Associations of practice characteristics and adoption with 
review activity
Table 2 shows the coefficients for the associations of the 
respective explanatory variables with reach, maintenance 
and delivery to patient. Since all explanatory variables 
were dichotomised, the coefficients reflect the mean 
absolute differences in the outcome variable between 
the two categories of explanatory variables (eg, reach 
was 20.7 percentage points lower in large compared 
with small). In multivariate analyses, being a registered 
GP training practice was the only practice characteristic 
significantly associated with review activity (delivery to 
patient), in that being a training practice was a predictor 
of a lower proportion of patients having their high-risk 
prescribing changed or actively followed up (despite 
the fact that baseline levels of high-risk prescribing were 
comparable between training and non-training prac-
tices (3.8% vs 3.5%) and not significantly associated 
with review activity). With respect to adoption variables, 
coherence and reflexive monitoring were significantly 
associated with a higher proportion of patients with high-
risk prescribing reviewed over the 48-week intervention 
period (reach), and reflexive monitoring was significantly 
associated with a higher proportion of patients having 
their high-risk prescribing changed or actively followed 
up (delivery to patient). Collective action was no longer 
significantly associated with reach in multivariate analysis 
after adjustment for coherence and reflexive monitoring 
(in the absence of evidence of significant collinearity (all 
VIFs<2)).
Associations of practice characteristics, adoption and review 
activity with effectiveness
Figure 3A ranks participating practices by effectiveness 
(the achieved relative reduction in NSAID or antiplatelet 
high-risk prescribing) and figure 3B shows the review 
activity in these practices. Practices with larger relative 
reductions in high-risk prescribing appeared to gener-
ally have reviewed higher proportions of patients (reach) 
and identified higher proportions of patients for proac-
tive follow-up (delivery to patient) than practices with 
smaller reductions, although there were exceptions. For 
example, the practices ranking 22nd and 23rd for effec-
tiveness, had relative reductions in high-risk prescribing 
of 19.3% and 19.0%, respectively, despite minimal review 
activity recorded in the informatics tool (and therefore 
no payment of financial incentives).
In multivariate model 1 (examining the relation-
ship between review activity and effectiveness while 
controlling for practice characteristics but not adoption 
variables), only reach remained significantly associated 
with effectiveness (although maintenance and delivery 
to patient were also significantly associated with effec-
tiveness in univariate analysis; there was no evidence of 
significant collinearity (VIF <2)). In multivariate model 2 
(when adoption variables were considered additionally), 
higher coherence and collective action were significantly 
associated with effectiveness, but reach and other review 
activity variables were not. Model 2 explained a substan-
tially larger proportion (adjusted R2=0.64) of variation in 
effectiveness compared with model 1 (adjusted R2=0.33) 
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Table 2 Associations of practice characteristics and adoption with review activity
Explanatory variables
% (95% CI) difference in 
reach
% (95% CI) difference in 
maintenance
% (95% CI) difference in 
delivery to patient
Univariate Multivariate Univariate Multivariate Univariate Multivariate
List size
(large vs small)
−20.7 (-40.3 to 
–1.2) P=0.04
NS −13.7 (−35.3 to 
7.8) P=0.20
NS −16.1 (−30.5 to 
–1.7) P=0.03
NS
% of patients 
aged≥75 years
(high vs low)
3.4 (−17.5 to 
24.4) P=0.74
NS 3.3 (−18.8 to 
25.4) P=0.76
NS 1.3 (−14.3 to 16.8) 
P=0.87
NS
Approved GP training 
practice
(yes vs no)
−24.9 (−46.6 to 
–3.2) P=0.02
NS −23.2 (−46.6 to 
0.14) P=0.05
NS −21.6 (−37.1 to 
–6.0) P=0.008
−19.8 (-33.1 
to –6.6) 
P=0.005
% of patients in most 
deprived quintile
(high vs low)
−3.0 (−23.9 to 
18.0) P=0.77
NS −2.8 (−24.9 to 
19.4) P=0.80
NS −6.1 (−21.5 to 
9.30) P=0.42
−10.1 (−21.8 
to 1.6) 
P=0.09
% baseline high-risk 
prescribing
(high vs low)
4.9 (−16.0 to 
25.8) P=0.63
NS 5.8 (−16.3 to 
27.8) P=0.60
NS 0.8 (−14.8 to 16.4) 
P=0.92
NS
% coherence (whether 
practices understand and 
value intervention aims and 
processes)
(high vs low)
12.0 (−9.8 to 
33.8) P=0.27
16.9 (1.06 to 
32.7) P=0.04
8.1 (−15.2 to 
31.4) P=0.48
NS 13.0 (−2.82 to 
28.8) P=0.10
NS
% cognitive participation 
(whether practices engage 
with and plan to implement) 
(high vs low)
7.2 (−14.4 to 
28.8) P=0.50
NS 3.3 (−19.7 to 
26.3) P=0.77
NS 8.1 (−7.75 to 24.0) 
P=0.30
NS
% collective action 
(whether practices 
effectively implement in the 
context of existing work) 
(high vs low)
25.7 (7.0 to 
44.4) P=0.009
NS 30.3 (11.1 to 
49.5) P=0.003
NS 13.8 (−0.88 to 
28.6) P=0.06
NS
% reflexive monitoring 
(whether practices 
evaluated and if necessary 
modify the implementation) 
(high vs low)
30.1 (12.2 to 
48.0) P=0.002
26.4 (9.9 to 
42.9) P=0.003
28.4 (10.6 to 
46.2) P=0.003
28.4 (10.6 
to 46.2) 
P=0.003
23.9 (10.9 to 36.8)
P=0.001
18.8 (7.2 
to 30.3) 
P=0.003
R2 for multivariate model 
(adjusted for number of 
variables*)
0.39 (0.34) 0.28 (0.25) 0.52 (0.46)
*The adjusted R2 was calculated as 1−((1 R2)×(N−1)/(N−P−1)), where R2 is sample R-square, P is number of and n is total sample size.
GP, general practitioner; NS, not significantly associated in multivariate model so dropped.
(table 3). The results of the sensitivity analyses were 
consistent with the primary analyses findings (see online 
supplementary appendix 3).
dIscussIOn
summary of findings
In this analysis of quantitative data from the process eval-
uation of the DQIP trial, lower QOF performance was 
found to be the only practice characteristic that was statis-
tically significantly associated with willingness to partic-
ipate in DQIP, consistent with recruited practices not 
being higher performing in general. Across all practices, 
there was large variation in both recorded review activity 
(reach and maintenance each ranging from 0.0% to 
100%, delivery to patient ranging from 0.0% to 83.3%), 
and effectiveness (ranging from a relative increase of 
24.1% to a relative reduction of 77.2%, although 30/33 
practices had a reduction of some kind in the targeted 
prescribing). With respect to factors explaining variation 
in review activity, higher adoption was significantly asso-
ciated with higher review activity (coherence with reach, 
and reflexive monitoring with all three of reach, main-
tenance and delivery to patient). Being a training prac-
tice was significantly associated with lower review activity 
(delivery to patient) despite comparable levels of baseline 
high-risk prescribing in training (3.8%) and non-training 
practices (3.5%). This was somewhat unexpected since 
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Figure 3 Variation among practices in effectiveness (A) and review activity (B).
the general expectation is that training practices will 
have higher quality, and further research to examine this 
would be of interest.
With respect to factors explaining variation in effective-
ness, higher baseline high-risk prescribing was associated 
with larger reductions in high-risk prescribing, which is 
likely to reflect larger scope for improvement. Higher 
review activity was also significantly associated with effec-
tiveness after adjustment for practice characteristics, 
with practice characteristics and review activity together 
explaining 38.5% of variation in effectiveness. However, 
when adoption variables were additionally introduced 
into the model, review activity was no longer inde-
pendently associated with effectiveness. The final model 
comprising baseline high-risk prescribing, coherence 
and collective action as explanatory variables explained 
a substantive amount (64%) of variation in effectiveness 
between practices.
strengths and limitations
A major strength of this study is that we were able to collect 
detailed quantitative data on how practices responded to 
the DQIP intervention (in terms of adoption and review 
activity) from all participating practices while the inter-
vention was live. This enabled us to examine substantial 
heterogeneity in both the implementation of intervention 
processes and effectiveness, thereby complementing qual-
itative case studies examining practitioners’ perceptions 
of practices’ responses. However, our study also has some 
limitations. First, as with most cluster-randomised trials, 
the sample size was small (33 practices) reflecting that it 
is driven by the power calculation for the main trial rather 
than being driven by the process evaluation. This has a 
number of implications including risk of biased overesti-
mation of explained variation (which we accounted for by 
reporting an adjusted R2 value) and risk of overfitting of 
models (as a result of which we dropped several margin-
ally significant (0.05<P<0.1) variables from final models, 
and our fitted model has at least 10 practices per variable 
which is adequate in view of simulation studies showing 
that a minimum of only two SPV may suffice in linear 
regression for adequate estimation of regression coeffi-
cients).24 More problematically, there is relatively limited 
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Table 3 Associations of practice characteristics, adoption and review activity with effectiveness
Explanatory variables
% (95% CI) difference in 
effectiveness (univariate)
% (95% CI) difference in 
effectiveness (multivariate 
model 1—practice 
characteristics and review 
activity only)
% (95% CI) difference in 
effectiveness (multivariate 
model 2—all variables)
Practice characteristics
  List size
  (large vs small)
−12.9 (−31.8 to 5.9), P=0.17 NS NS*
  % of patients aged≥75 years 
(high vs low)
3.5 (−15.9 to 22.8), P=0.72 NS NS†
  Training status
  (yes vs no)
−18.8 (−39.5 to 1.8), P=0.07 NS NS
  % of patients in most deprived 
postcodes (high vs low)
−7.6 (-26.8 to –11.6), P=0.42 NS NS
  % baseline high-risk prescribing
  (high vs low)
23.2 (5.8 to 40.6), P=0.01 19.6 (4.0 to 35.3), P=0.02 13.9 (-0.12 to 27.9), P=0.05
Review activity
  % reach (high vs low) 26.5 (9.7 to 43.3), P=0.003 23.6 (7.9 to 39.2), P=0.004 NS
  % maintenance (high vs low) 18.9 (0.8 to 37.1), P=0.04 NS NS
  % delivery to patient (high vs 
low)
24.9 (7.7 to 42.0), P=0.006 NS NS
Adoption
  % ‘coherence’ (high vs low) 25.3 (6.9 to 43.7), P=0.009 Not examined 22.2 (7.8 to 36.5), P=0.004
  % ‘cognitive participation’ (high 
vs low)
3.8 (−16.3 to 23.9), P=0.70 Not examined NS
  % ‘collective action’ (high vs low) 32.1 (16.7 to 47.6), P<0.001 Not examined 30.1 (17.4 to 42.9), P<0.001
  % ‘reflexive monitoring’ (high vs 
low)
21.9 (4.1 to 39.6), P=0.02 Not examined NS
  R2 for multivariate model 
(adjusted for number of 
variables‡)
0.38 (0.33) 0.68 (0.64)
*Retained in the initial model as P=0.07 (criteria for retaining P<0.1) but dropped to avoid overfitting given the small number of practices.
†Retained in the initial model as P=0.08 (criteria for retaining P<0.1) but dropped to avoid overfitting given the small number of practices.
‡The adjusted R2 was calculated as 1−[(1 R2)*(N−1)/(N−P1)], where R2 is sample R-square, P is number of predictors and n is total sample 
size.
NS, not significantly associated in multivariate model so dropped.
power for identifying practice characteristics significantly 
associated with trial participation, and for examining vari-
ation in intervention implementation and outcomes. Our 
decision to dichotomise continuous explanatory variables 
further reduced power, but as described above we believe 
it is necessary to enhance interpretability for an improve-
ment audience and our findings demonstrate that vari-
ables associated with a 20% or larger absolute difference 
in review activity and effectiveness could be identified 
as statistically significant. In addition, sensitivity anal-
yses that fitted predictor variables as continuous yielded 
findings consistent with the primary analyses (see online 
supplementary appendix 3).
Second, reflecting limited resources and the lack of 
any existing NPT instruments at the time of the study, we 
limited examination of practice characteristics to those 
that could be measured using publicly available data 
sources and we took a pragmatic approach to the devel-
opment and administration of the two NPT-informed 
adoption surveys. Although face and content validity was 
confirmed by a panel of NPT experts, time constraints 
meant that we were unable to conduct psychometric 
testing. We also pragmatically limited scoring of the ques-
tionnaires to the DQIP lead in each practice rather than 
including all professionals targeted by the intervention. 
Given evidence of substantial variation in the tendency 
to issue high-risk prescriptions of NSAIDs between GPs 
in the same practice,25 it is plausible that perceptions of 
targeted high-risk prescribing and (by extension) the 
value of the intervention may differ between different 
team members. Although the questionnaires also sought 
perceptions of the participating GP regarding the prac-
tice as a whole, future research should aim to elicit how 
valid such perceptions are. The adoption analysis should 
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therefore be considered exploratory, but it is interesting 
that scores on the adoption surveys explained a large 
proportion of variation in effectiveness, indicating the 
potential for the use of NPT-based surveys for measuring 
the adoption of complex interventions by clinical teams. 
In addition, the survey findings are consistent with 
reported implementation processes elicited by interviews 
and observations in 10 case-study practices19 (see online 
supplementary appendix 4). While the instruments 
used here were study specific, a generic instrument to 
measure NPT implementation processes has since been 
developed.26
Third, our measure of effectiveness (change from the 
baseline period to the second half of the intervention 
period) is vulnerable to secular trends since the anal-
ysis did not account for time trends (although there was 
no evidence of an overall secular trend in the primary 
analysis12). Finally, our measures of review activity are 
all derived from the DQIP informatics tool and some 
practices may have carried out reviews or other improve-
ment activity without recording it in the tool. Practices 
only received payment if they completed a review in the 
tool, which would be expected to make recording more 
complete, but several practices with large reductions in 
prescribing recorded few if any reviews. In the main trial 
analysis, the intervention was also found to significantly 
reduce new high-risk prescribing.12 This is consistent 
with the intervention having effects beyond those directly 
attributable to the review of ongoing prescribing, which 
was the main target of the intervention and process evalu-
ation measurement. Our measurement of ‘review activity’ 
is therefore likely to be an incomplete assessment of 
activity triggered by the intervention. This is consistent 
with the findings of the case study which identified other 
work being done in practices beyond that required by 
the trial team, including work by GPs to minimise the 
restarting of medicines where there had been an active 
decision to stop.19
The findings complement the two accompanying 
process evaluation papers.19 20 Participants perceived that 
all intervention components delivered to the practice by 
the research team were active,19 20 which is consistent with 
the findings of overall high adoption and review activity, 
and the observation that 30/33 practices had at least 
some reduction in targeted high-risk prescribing. The 
quantitative findings are also consistent with the findings 
of the mixed methods case-study evaluation of interven-
tion adoption and implementation of review activity by 
practices, in that most of the case-study practices sampled 
for not having initially reduced their high-risk prescribing 
were found to actually have delayed implementation and 
had reduced their high-risk prescribing by the end of 
the trial.19 The case-study evaluation identifies that there 
are additional improvement processes happening which 
are not captured by our measures of review activity, high-
lighting the value of in-depth qualitative examination 
of implementation in a sample of practices alongside 
broader quantitative examination in all practices.19
Implications
In order to reduce patient exposure to high-risk 
prescribing, the DQIP intervention was designed to use 
education, informatics and financial incentives to acti-
vate GPs and practices to review patients with ongoing 
high-risk prescribing, where documentation of reviews 
in the DQIP tool was required to obtain payment. We 
therefore hypothesised that adoption of the intervention 
(measured in terms of the four NPT constructs coherence, 
cognitive participation, collective action and reflexive 
monitoring) would stimulate review activity (measured 
in terms of reach, maintenance and delivery to patient) 
documented in the DQIP tool, which in turn would trans-
late into reductions in high-risk prescribing. We found 
significant associations between adoption and review 
activity (in both univariate and multivariate analysis) and 
between review activity and effectiveness (in univariate 
analysis and in multivariate analysis after adjustment for 
practice characteristics only), which generally supports 
the hypothesised mechanism of action. However, the 
association between review activity and effectiveness was 
no longer significant after adoption variables had been 
introduced into the multivariate model and the inclusion 
of adoption versus review activity variables in the model 
explained a substantially larger proportion of variation 
in effectiveness. This was somewhat surprising, because 
it suggests that DQIP adoption (as defined and measured 
in this study) impacted on the outcome in ways beyond 
those primarily targeted by the DQIP intervention 
(ie, review and proactive management of ongoing high-
risk prescribing). Given the relatively small sample size, 
we did not attempt to conduct a formal mediation anal-
ysis27 and these findings should therefore be interpreted 
with caution. Nevertheless, our results are consistent with 
the main trial finding of significant reductions in the initi-
ation of high-risk prescribing which was not the primary 
target of the intervention (in addition to reductions in 
ongoing prescribing which was the primary target).12 One 
limitation of the DQIP intervention was its narrow focus 
on two classes of medicines (NSAIDs and antiplatelets). 
The combined findings of the main trial and this process 
evaluation suggest that it may be possible to extend the 
scope of targeted high-risk prescribing without risking 
a rebound in the high-risk prescribing targeted here. 
Whether this is the case and whether facilitating and 
incentivising review of other potentially suboptimal care 
more generally lead to changes in sustained changes in 
professional behaviour is an interesting area for future 
research.
cOnclusIOn
Despite the large overall reductions in high-risk 
prescribing observed in the DQIP trial, the findings from 
this quantitative process evaluation demonstrate substan-
tial variation between practices in terms of their response 
to the intervention and effectiveness, the latter being 
partially explained by differences in baseline high-risk 
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prescribing. Our findings suggest that the overall impact 
of the DQIP intervention was significantly mediated by its 
impact on new high-risk prescribing or its re-initiation. 
The adoption processes coherence (whether practices 
understand and value intervention processes and aims) 
and collective action (whether practices effectively imple-
ment the intervention in the context of existing work) 
could be targets for further refinement of the DQIP inter-
vention in order to achieve a more consistent interven-
tion effect and further enhance effectiveness.
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